In recent years, the arrival of the immunotherapy industry has introduced the possibility of providing transformative, durable, and potentially curative outcomes for various forms of malignancies. However, further research has shown that there are a number of issues that significantly reduce the effectiveness of immunotherapy, especially in solid tumors. First of all, these problems are related to the protective mechanisms of the tumor and its microenvironment. Currently, major efforts are focused on overcoming protective mechanisms by using different adoptive cell therapy variants and modifications of genetically engineered constructs. In addition, a complex workforce is required to develop and implement these treatments. To overcome these significant challenges, innovative strategies and approaches are necessary to engineer more powerful variations of immunotherapy with improved antitumor activity and decreased toxicity. In this review, we discuss recent innovations in immunotherapy aimed at improving clinical efficacy in solid tumors, as well as strategies to overcome the limitations of various immunotherapies.
近年来,免疫治疗领域的兴起为多种恶性肿瘤提供了变革性、持久性乃至潜在治愈可能。然而,进一步研究表明,存在诸多因素显著降低免疫治疗效果,尤其在实体瘤治疗中更为突出。这些问题首先与肿瘤及其微环境的保护机制密切相关。目前研究重点主要集中于通过不同形式的过继性细胞疗法及基因工程构建体修饰来突破这些保护机制。此外,这类疗法的开发与实施需要复合型专业人才团队的支持。为应对这些重大挑战,亟需创新性策略与方法,以构建抗肿瘤活性更强、毒性更低的免疫治疗新方案。本综述将探讨当前旨在提升实体瘤临床疗效的免疫治疗创新进展,以及克服各类免疫疗法局限性的应对策略。